Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2004-06-01
2008-10-21
Anderson, Rebecca L (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C546S159000, C546S275700, C546S277400
Reexamination Certificate
active
07439363
ABSTRACT:
The present invention is directed to novel indazolyl-substituted pyrroline compounds of Formula (I):R2is selected from the group consisting of —C1-8alkyl-Z, —C2-8alkenyl-Z and —C2-8alkynyl-Z; wherein the —C1-8alkyl-Z, —C2-8alkenyl-Z and —C2-8alkynyl-Z and Z is a 5 to 6 member aromatic monocyclic heteroaryl ring having from 2 to 4 heteroatoms. These compounds are useful as kinase or dual-kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase or dual-kinase mediated disorder.
REFERENCES:
patent: 5057614 (1991-10-01), Davis et al.
patent: 5624949 (1997-04-01), Heath, Jr. et al.
patent: 5721245 (1998-02-01), Davis et al.
patent: 6849643 (2005-02-01), Zhang et al.
patent: 6987110 (2006-01-01), Zhang et al.
patent: 7125878 (2006-10-01), Zhang et al.
patent: 2004/0054180 (2004-03-01), Zhang et al.
patent: 2004/0192718 (2004-09-01), Zhang et al.
patent: 2004/0259928 (2004-12-01), Zhang et al.
patent: 2005/0004202 (2005-01-01), Zhang et al.
patent: WO 98/11102 (1998-03-01), None
patent: WO 00/06564 (2000-02-01), None
patent: WO 00/21927 (2000-04-01), None
patent: WO 03/104222 (2003-12-01), None
PCT International Search Report, dated Oct. 6, 2004 for PCT/US2004/017375.
Lijam et al, “Social Interaction and Sensorimotor Gating Abnormalities in Mice LackingDVl1,” Cell, 1997, pp. 895-905, vol. 90, Cell Press.
Eldar-Finkelman et al, “Increased Glycogen Synthase Kinase-3 Activity in Diabetes-and Obesity-Prone C57BL/6J Mice,” Diabetes, 1999, pp. 1662-1666, vol. 48.
Eastman et al, “Regulation of LEF-1/TCF transportation factors by Wnt and other signals,” Current Opinion in Cell Biology, 1999, pp. 233-240, vol. 11, Elsevier Science Ltd ISSN 0955-0674.
Ikeda et al, “Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3β-dependent phosphorylation of β-catenin,” The EMBO Journal, 1998, pp. 1371-1384, vol. 17, No. 5, Oxford University Press.
Manji et al, “Modulation of CNS signal Transduction Pathways and Gene Expression by Mood-Stabilizing Agents: Therapeutic Implications,” J Clin Psychiatry, 1999, vol. 60, Suppl 2.
Eldar-Finkelman et al, “Phosphorylation of insulin receptor substrate 1 by glycogen synthase kinase 3 impairs insulin action,” Cell Biology, 1997, pp. 9660-9664, vol. 94, Proc Natl Acad Sci, USA.
Hoeflich et al, “Requirement for glycogen synthase kinase-3β in cell survival and NF-KB activation,” Nature, 2000, pp. 86-90, vol. 406, Macmillan Magazines, Ltd.
Pap et al, “Role of Glycogen Synthase Kinase-3 in the Phosphatidylinosotol 3-Kinase/Akt Cell Survival Pathway,” The Journal of Biological Chemistry, pp. 19929-19932, 1998, vol. 273, No. 32, The American Society for Biochemistry and Molecular Biology, Inc. USA.
Hong et al, “Lithium Reduces Tau Phosphorylation by Inhibition of Glycogen Synthase Kinase-3*,” The Journal of Biological Chemistry, 1997, pp. 25326-25332, vol. 272, No. 40, The American Society for Biochemistry and Molecular Biology, Inc., USA.
D'Mello et al, “Lithium Induces Apoptosis in Immature Cerebellar Granule Cells but Promotes Survival of Mature Neurons,” 1994, Experimental Cell Research, pp. 332-338, vol. 211, Academic Press, Inc.
Srivastava et al, “Potential mechanism (s) involved in the regulation of glycogen synthesis by insulin,” Molecular and Cellular Biochemistry, 1998, pp. 135-141, vol. 182, Kluwer Publishers, Netherlands.
Rotenberg et al, “Protein Kinase C in Neoplastic Cells,” Biochemical and Molecular Aspects of Selected Cancers, 1991, pp. 25-73, vol. 1, Academic Press, Inc.
Inoguchi et al, “Preferential elevation of protein kinase C isoform βII and diacylglycerol levels in the aorta and heart of diabetic rats: Differential reversibility to glycemic control by islet cell transporatation,” Pro. Natl Acad Sci, 1992, pp. 11059-11063, vol. 89, USA.
Xia et al, “Characterization of Vascular Endothelial Growth Factor's Effect on the Activatation of Protein Kinase C, It Isoforms, and Endothelial Cell Growth,” J Clin Invest., 1996, pp. 2018-2026, vol. 98, No. 9, The American Society for Clinical Investigation, Inc.
Bilder et al, “Phorbol-12, 13-Dibutyrate-Induced Vasoconstriction in Vivo: Characterization of Response in Genetic Hypertension,” The Journal of Pharmacology and Experimental Therapeutics, 1990, pp. 526-530, vol. 252, No. 2, The American Society for Pharmacology and Experimental Therapeutics.
Ishii et al, “Amelioration of Vascular Sysfunctions in Diabetic Rats by an Oral PKC β Inhibitor,” Science, 1996, pp. 728-731, vol. 272.
Hsieh et al, “Phosphorylation of the Human Vitamin D Receptor by Protein Kinase C,” The Journal of Biological Chemistry, 1993, pp. 15118-15126, vol. 268, No. 20, The American Society for Biochemistry and Molecular Biology, Inc., USA.
Murray et al, “Protein Kinase C Isotypes in Human Erythroleukemia (K562) Cell Proliferation and Differentiation,” The Journal of Biological Chemistry, 1993, pp. 15847-15853, vol. 268, No. 21, The American Society for Biochemistry and Molecular Biology, Inc., USA.
Yan et al, “Protein Kinase C-β and Oxygen Deprivation,” The Journal of Biological Chemistry, 2000, pp. 11921-11928, vol. 275, No. 16, The American Society for Biochemistry and Molecular Biology, Inc., USA.
Matsumoto et al, “Staurosporine, a protein Kinase C Inhibitor interferes with proliferation of arterial smooth muscle cells,” Biochemical and Biophysical Research Communications, 1989, pp. 105-109, vol. 158, No. 1, Academic Press, Inc.
Muid et al, “A novel conformationally restricted protein kinase C inhibitor, Ro31-8425, inhibits human neutrophil superoxide generation by soluble, particulate and post-receptor stimuli,” FEBS 10406, 1991, pp. 169-172, No. 1, 2, Federal of European Biochemical Societies.
Toullec et al, “The Bisindolymaleimide GF 109203X is a Potent and Selective Inhibitor of Protein Kinase C,” The Journal of Biological Chemistry, 1991, pp. 15771-15781, vol. 266, No. 24, The American Society for Biochemistry and Molecular Biology, Inc.
Huang et al, “The mechanism of protein kinase C activation,” Trends Neuroscience, 1989, pp. 425-32, vol. 12, No. 11, Elsevier Science Publishers, Ltd. UK.
Sauma et al, “Protein Kinase Cβ1 and Protein Kinase Cβ1 and Protein Kinase Cβ2 Activate p. 57 Mitogen-activated Protein Kinase and Block Differentiation in Colon Carcinoma Cells,” Cell Growth and Differentiation, 1996, pp. 587-594, vol. 7.
Kobayashi et al, “Platelet-activating factor modulates microvascular transport by stimulation of protein kinase C,” The American Physiological Society, 1994, pp. 1214-20.
Chin et al, “Overexpression of Protein Kinase C Isoenzymes α, βI, γ, and ε in Cells Overexpressing the Insulin Receptor,” The Journal of Biological Chemistry, 1993, pp. 6338-47, vol. 268. No. 9, The American Society for Biochemstry and Molecular Biology, Inc., USA.
Ren et al, “Protein kinase C-β mediates lipoprotein-induced generation of PAI-1 from vascular endothelial cells,” America Jouranl Physiol. Endocrinol Metab., 2000, pp. 656-662, vol. 278.
Karasik et al, “Increased Protein Kinase C Activity is Linked to Reduced Insulin Receptor Autophosphorylation in Liver of Starved rats*,” The Journal of Bilogical Chemistry, 1990, pp. 10226-10231, vol. 265, No. 18, The American Society for Biochemistry and Molecular Biology, Inc., USA.
Lee et al, “Differential Regulation of Prtein Kinase C and (Na,K)-Adenosine Triphosphatase Activities by Elevated Glucose Levels in Retninal Capillary Endothelial Cells,” J. Clin Invest., 1989, pp. 90-94, vol. 83, The American Society for Clinical Investigation, Inc.
Wolf et al, “Diacylglycerol Accumulation and
Maryanoff Bruce E.
Ye Hong
Zhang Han-Cheng
Anderson Rebecca L
Janssen Parmaceutica N.V.
Stercho Yuiry
Young Shawquia
LandOfFree
Substituted indazoly(indoly)maleimide derivatives as kinase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted indazoly(indoly)maleimide derivatives as kinase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted indazoly(indoly)maleimide derivatives as kinase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4015570